



Lilly Cares® Foundation 2022 State-Level Results

Diabetes Medications		
BAQSIMI® (glucagon) nasal powder; Basaglar® (insulin glargine injection); Glucagon™ (glucagon for injection); Humalog® (insulin lispro injection); Humulin® (human insulin); Lyumjev® (insulin lispro-aabc) injection; Trulicity® (dulaglutide) injection		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$610,000	64
AL	\$46,300,000	4899
AR	\$13,800,000	1284
AZ	\$20,700,000	2070
CA	\$51,500,000	5266
CO	\$11,300,000	1154
CT	\$6,500,000	658
DC	\$260,000	30
DE	\$4,600,000	439
FL	\$91,800,000	9413
GA	\$73,700,000	7632
HI	\$860,000	84
IA	\$12,800,000	1192
ID	\$11,800,000	1206
IL	\$45,900,000	4318
IN	\$76,000,000	6989
KS	\$24,400,000	2515
KY	\$28,700,000	2811
LA	\$28,300,000	2851
MA	\$18,000,000	1714
MD	\$22,800,000	2232
ME	\$9,100,000	946
MI	\$77,500,000	7177
MN	\$23,600,000	2303
MO	\$47,300,000	4674
MS	\$20,700,000	2066
MT	\$5,100,000	510
NC	\$110,900,000	11245
ND	\$2,600,000	241
NE	\$18,500,000	1856
NH	\$9,100,000	840
NJ	\$17,600,000	1833
NM	\$4,800,000	503
NV	\$10,700,000	1023
NY	\$42,600,000	4084
OH	\$111,300,000	9936
OK	\$25,300,000	2712
OR	\$15,900,000	1472
PA	\$68,500,000	6541
PR	\$430,000	49
RI	\$7,700,000	679
SC	\$36,100,000	3633
SD	\$4,100,000	430
TN	\$66,900,000	6404
TX	\$207,000,000	22083
UT	\$18,800,000	1730
VA	\$58,000,000	6009
VI	\$45,000	5
VT	\$1,100,000	108
WA	\$20,100,000	1927
WI	\$41,800,000	3893
WV	\$15,200,000	1439
WY	\$3,100,000	362

BAQSIMI®, Basaglar®, Humalog®, Humulin®, Lyumjev® and Trulicity® are registered trademarks and Glucagon™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.



Lilly Cares® Foundation 2022 State-Level Results

Mental Health Medications		
Cymbalta® (duloxetine delayed-release capsules); Prozac® (fluoxetine); Strattera® (atomoxetine); Symbyax® (olanzapine and fluoxetine); Zyprexa® (olanzapine)		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AL	\$3,900,000	862
AR	\$110,000	23
AZ	\$110,000	27
CA	\$450,000	82
CO	\$110,000	25
CT	\$57,000	11
DC	\$4,000	1
DE	\$43,000	6
FL	\$4,500,000	934
GA	\$9,600,000	1572
HI	\$23,000	3
IA	\$72,000	15
ID	\$150,000	37
IL	\$330,000	69
IN	\$1,200,000	252
KS	\$2,700,000	422
KY	\$440,000	104
LA	\$410,000	85
MA	\$82,000	16
MD	\$310,000	64
ME	\$300,000	65
MI	\$480,000	109
MN	\$260,000	52
MO	\$2,100,000	420
MS	\$1,400,000	275
MT	\$200,000	47
NC	\$10,400,000	1786
ND	\$130,000	17
NE	\$510,000	104
NH	\$190,000	36
NJ	\$230,000	38
NM	\$32,000	6
NV	\$36,000	8
NY	\$350,000	57
OH	\$750,000	155
OK	\$2,500,000	462
OR	\$260,000	57
PA	\$1,000,000	192
RI	\$37,000	10
SC	\$1,000,000	187
SD	\$2,100,000	315
TN	\$3,200,000	521
TX	\$49,800,000	8324
UT	\$200,000	33
VA	\$4,200,000	755
VT	\$8,000	2
WA	\$250,000	45
WI	\$380,000	77
WV	\$350,000	70
WY	\$350,000	74

Cymbalta®, Prozac®, Strattera®, Symbyax®, and Zyprexa® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.



Lilly Cares® Foundation 2022 State-Level Results

Cancer Medications		
Alimta® (pemetrexed for injection); Cyramza® (ramucirumab) injection; Erbitux® (cetuximab) injection; Portrazza® (necitumumab) injection; Retevmo® (selpercatinib); Verzenio® (abemaciclib)		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$600,000	6
AL	\$9,100,000	155
AR	\$5,300,000	82
AZ	\$16,200,000	209
CA	\$40,300,000	471
CO	\$11,200,000	144
CT	\$6,200,000	76
DC	\$180,000	3
DE	\$1,300,000	16
FL	\$56,500,000	774
GA	\$18,300,000	258
HI	\$2,200,000	24
IA	\$4,600,000	53
ID	\$3,900,000	46
IL	\$21,100,000	265
IN	\$13,500,000	166
KS	\$7,700,000	94
KY	\$7,900,000	98
LA	\$5,600,000	75
MA	\$8,400,000	101
MD	\$10,100,000	121
ME	\$3,800,000	45
MI	\$13,100,000	158
MN	\$12,300,000	144
MO	\$14,000,000	185
MS	\$6,000,000	84
MT	\$1,800,000	19
NC	\$25,000,000	326
ND	\$1,200,000	14
NE	\$4,000,000	49
NH	\$1,900,000	34
NJ	\$20,600,000	252
NM	\$2,200,000	30
NV	\$5,300,000	65
NY	\$26,400,000	320
OH	\$27,700,000	355
OK	\$5,500,000	76
OR	\$9,400,000	106
PA	\$24,100,000	301
PR	\$920,000	10
RI	\$1,900,000	23
SC	\$8,200,000	155
SD	\$1,700,000	22
TN	\$17,600,000	233
TX	\$80,100,000	1002
UT	\$6,400,000	74
VA	\$16,900,000	231
VI	\$180,000	2
VT	\$1,300,000	16
WA	\$13,000,000	166
WI	\$11,700,000	131
WV	\$4,200,000	54
WY	\$490,000	5

Alimta®, Cyramza®, Erbitux®, Portrazza®, Retevmo® and Verzenio® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares® Foundation 2022 State-Level Results

Other Medications		
Cialis® (tadalafil); Emgality® (galcanezumab-gnlm) injection; Evista® (raloxifene hydrochloride); Forteo® (teriparatide injection); Humatrope® (somatropin) for injection; Olumiant® (baricitinib); REYVOW® (lasmiditan); Taltz® (ixekizumab) injection		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$900,000	26
AL	\$21,600,000	681
AR	\$26,300,000	487
AZ	\$18,000,000	461
CA	\$55,500,000	1360
CO	\$16,100,000	425
CT	\$6,200,000	151
DC	\$140,000	3
DE	\$4,000,000	88
FL	\$97,000,000	3096
GA	\$46,100,000	1231
HI	\$2,900,000	49
IA	\$7,900,000	239
ID	\$13,100,000	304
IL	\$30,300,000	708
IN	\$35,600,000	862
KS	\$12,500,000	307
KY	\$14,900,000	409
LA	\$23,200,000	540
MA	\$15,300,000	320
MD	\$8,800,000	239
ME	\$5,700,000	122
MI	\$33,300,000	787
MN	\$18,200,000	431
MO	\$31,100,000	832
MS	\$10,000,000	353
MT	\$3,900,000	114
NC	\$46,300,000	1362
ND	\$2,900,000	75
NE	\$5,400,000	163
NH	\$4,900,000	127
NJ	\$24,100,000	503
NM	\$3,400,000	78
NV	\$6,100,000	158
NY	\$32,500,000	760
OH	\$44,000,000	1014
OK	\$19,500,000	446
OR	\$12,800,000	267
PA	\$34,100,000	865
PR	\$3,000,000	58
RI	\$2,700,000	62
SC	\$18,300,000	504
SD	\$4,700,000	152
TN	\$29,500,000	759
TX	\$107,900,000	2676
UT	\$10,600,000	270
VA	\$20,900,000	638
VT	\$980,000	28
WA	\$19,800,000	464
WI	\$23,300,000	568
WV	\$7,000,000	161
WY	\$1,300,000	53

Cialis®, Emgality®, Evista®, Forteo®, Humatrope®, Olumiant®, REYVOW® and Taltz® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.